Articles by Dawn M. Boothe, DVM, PhD, DACVIM, DACVCP

Apr 1, 2009
By: Dawn M. Boothe, DVM, PhD, DACVIM, DACVCP

Increasingly, the veterinary practitioner will find that the favorite drug of choice is no longer a viable option. The role of resistance in therapeutic failure of antimicrobials is well established.

Biotherapeutics: Pre, pro and synbiotics in small animals (Proceedings)

Apr 1, 2009
By: Dawn M. Boothe, DVM, PhD, DACVIM, DACVCP

The concept that microbes might be beneficial, rather than simply detrimental, to health, enjoys a long history of anectodal evidence.

The perils of compounding (Proceedings)

Apr 1, 2009
By: Dawn M. Boothe, DVM, PhD, DACVIM, DACVCP

Compounding is and always has been a critical component to the provision of individualized drug care to the small animal patient.

Nonsteroidal anti-inflammatories in cats (Proceedings)

Apr 1, 2009
By: Dawn M. Boothe, DVM, PhD, DACVIM, DACVCP

The cat as a species represents a therapeutic challenge when trying to use NSAIDs safely.

Non-glucocorticoid immunomodulation in small animals (Proceedings)

Aug 1, 2008
By: Dawn M. Boothe, DVM, PhD, DACVIM, DACVCP

Despite their marked efficacy in suppressing the immune system, alternatives to glucocorticoids must often be considered when treatment immune-mediated or chronic allergic diseases in dogs and cats.

Too much of a good thing: Update on NSAID therapy (Proceedings)

Aug 1, 2008
By: Dawn M. Boothe, DVM, PhD, DACVIM, DACVCP

The principles of pharmacology upon which a dosing regimen is based, and the impact of disease in the critical patient were discussed in the companion manuscript entitled "Adjusting Doses" in this same proceedings.

Role of glucocorticoids in the treatment of chronic allergic diseases (Proceedings)

Aug 1, 2008
By: Dawn M. Boothe, DVM, PhD, DACVIM, DACVCP

For good reasons, glucocorticoids (GLs) have been the cornerstone of immunosuppressive therapy in humans and animals.

What's new in small-animal drug therapy (Proceedings)

Aug 1, 2008
By: Dawn M. Boothe, DVM, PhD, DACVIM, DACVCP

A test is available to detect the MDR-1 genetic deletion that leads to P-glycoprotein deficiencies in collies and related breeds.

Antimicrobial therapy: The role of susceptibility testing (Proceedings)

Aug 1, 2008
By: Dawn M. Boothe, DVM, PhD, DACVIM, DACVCP

"Even experienced practitioners may not realize that giving a patient antibiotics affects not just that patient, but also their environment, and all the other people that come into contact with that environment."

« Previous

123